News

Fable Therapeutics Appoints David J. Baker, PhD, as Chief Scientific Officer
Fable Therapeutics, a discovery-stage biotechnology company developing purpose-built biologics powered by state-of-the-art structure and sequence-based protein language models, today announced the ...
Medscape4d
Sibeprenlimab Halves uPCR in IgA Nephropathy Trial
The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent ...
Medscape5d
Combination Therapy Offers CONFIDENCE to CKD+T2D Patients
Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...
The Lancet5d
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 ...
cCentre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health ...
C&EN6d
Multiobjective Optimization of Pharmacophore Hypotheses: Bias Toward Low-Energy Conformations
Department of Information Studies, University of Sheffield, Regent Court, 211 Portobello Street, Sheffield S1 4DP, United Kingdom, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire, United ...